Zentalis Pharmaceuticals Ownership | Who Owns Zentalis Pharmaceuticals?


OverviewForecastRevenueFinancialsChart

Zentalis Pharmaceuticals Ownership Summary


Zentalis Pharmaceuticals is owned by 77.26% institutional investors, 13.54% insiders, and 9.20% retail investors. Matrix capital management company, lp is the largest institutional shareholder, holding 19.39% of ZNTL shares. Eventide Healthcare & Life Sciences I is the top mutual fund, with 3.96% of its assets in Zentalis Pharmaceuticals shares.

ZNTL Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockZentalis Pharmaceuticals77.26%13.54%9.20%
SectorHealthcare Stocks 488.17%11.08%-399.26%
IndustryBiotech Stocks 306.59%11.10%-217.69%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Matrix capital management company, lp13.96M19.39%$16.19M
Blackrock4.82M6.80%$19.71M
Vanguard group3.27M4.60%$9.91M
State street3.05M4.31%$12.48M
Acadian asset management2.80M3.89%$3.24M
Morgan stanley1.95M2.75%$7.98M
Opaleye management1.77M2.49%$5.36M
Blackrock funding, inc. /de1.74M2.42%$2.02M
Almitas capital1.60M2.22%$1.86M
Tang capital management1.55M2.15%$1.80M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Mayo clinic187.14K25.27%$765.41K
Matrix capital management company, lp13.96M7.27%$16.19M
Tybourne capital management (hk)1.48M4.96%$1.71M
Opaleye management1.77M0.94%$5.36M
Almitas capital1.60M0.47%$1.86M
Decheng capital1.32M0.39%$1.54M
5am venture management490.00K0.35%$1.48M
Pfizer953.83K0.19%$1.11M
Stonepine capital management109.01K0.12%$126.45K
Boxer capital450.00K0.10%$1.84M

Top Buyers

HolderShares% AssetsChange
Balyasny asset management970.86K0.00%970.86K
Morgan stanley1.95M0.00%913.31K
Opaleye management1.77M0.94%800.50K
Tybourne capital management (hk)1.48M4.96%516.67K
Jpmorgan chase859.71K0.00%370.51K

Top Sellers

HolderShares% AssetsChange
Fmr182.31K--4.89M
Eventide asset management---4.48M
Blackrock funding, inc. /de1.74M--2.49M
Vanguard group3.27M0.00%-1.34M
T. rowe price investment management---1.33M

New Positions

HolderShares% AssetsChangeValue
Cubist systematic strategies180.22K0.00%180.22K$546.08K
Bnp paribas arbitrage, snc176.29K0.00%176.29K$534.16K
Bridgeway capital management175.00K0.01%175.00K$530.25K
Ameriprise financial146.67K0.00%146.67K$444.42K
Rbf capital80.00K0.00%80.00K$92.80K

Sold Out

HolderChange
Gamma investing-2.00
Farther finance advisors-10.00
Nelson, van denburg & campbell wealth management group-11.00
Ifp advisors-23.00
Riggs asset managment-23.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2025115-12.21%55,620,77331.52%772.22%58-1.69%42-14.29%
Mar 31, 2025134-8.22%58,450,755-9.27%810.99%60-34.07%4963.33%
Dec 31, 20241390.72%61,824,330-12.88%860.87%8519.72%28-26.32%
Sep 30, 2024137-4.86%70,963,212-7.43%990.85%71-13.41%38-5.00%
Jun 30, 20241442.13%76,655,527-9.95%1080.75%825.13%4011.11%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Eventide Healthcare & Life Sciences I2.83M3.96%-2.12M
Vanguard US Total Market Shares ETF1.89M2.64%-
Eventide Gilead N1.64M2.30%-1.94M
Vanguard Total Stock Mkt Idx Inv1.55M2.14%-33.78K
Fidelity Growth Compy Commingled Pl O1.16M1.63%-
FIAM Small Cap Core CIT Cl B886.80K1.25%11.50K
Fidelity Growth Compy Commingled Pl S881.46K1.24%-280.77K
FIAM Small Cap Core Composite866.20K1.22%289.81K
Fidelity Small Cap Growth734.93K1.03%-
PRIMECAP Odyssey Aggressive Growth741.40K1.03%-172.00K

Recent Insider Transactions


DateNameRoleActivityValue
Apr 30, 2025Myers Scott Dunseth-Buy$29.37K
Feb 06, 2025Bruns Ingmar Chief Medical OfficerBuy$45.66K
Feb 03, 2025Vultaggio Vincent PAO and Interim PFOSell$4.48K
Feb 03, 2025Lackner Mark Chief Scientific OfficerSell$24.59K
Feb 03, 2025Paul Andrea Chief Legal OfficerSell$22.64K

Insider Transactions Trends


DateBuySell
2025 Q21-
2025 Q144
2024 Q4-1
2024 Q2-2
2024 Q1-6

ZNTL Ownership FAQ


Who Owns Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals shareholders are primarily institutional investors at 77.26%, followed by 13.54% insiders and 9.20% retail investors. The average institutional ownership in Zentalis Pharmaceuticals's industry, Biotech Stocks , is 306.59%, which Zentalis Pharmaceuticals falls below.

Who owns the most shares of Zentalis Pharmaceuticals?

Zentalis Pharmaceuticals’s largest shareholders are Matrix capital management company, lp (13.96M shares, 19.39%), Blackrock (4.82M shares, 6.80%), and Vanguard group (3.27M shares, 4.60%). Together, they hold 30.79% of Zentalis Pharmaceuticals’s total shares outstanding.

Does Blackrock own Zentalis Pharmaceuticals?

Yes, BlackRock owns 6.80% of Zentalis Pharmaceuticals, totaling 4.82M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 19.71M$. In the last quarter, BlackRock increased its holdings by 172.79K shares, a 3.72% change.

Who is Zentalis Pharmaceuticals’s biggest shareholder by percentage of total assets invested?

Mayo clinic is Zentalis Pharmaceuticals’s biggest shareholder by percentage of total assets invested, with 25.27% of its assets in 187.14K Zentalis Pharmaceuticals shares, valued at 765.42K$.

Who is the top mutual fund holder of Zentalis Pharmaceuticals shares?

Eventide Healthcare & Life Sciences I is the top mutual fund holder of Zentalis Pharmaceuticals shares, with 3.96% of its total shares outstanding invested in 2.83M Zentalis Pharmaceuticals shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools